Harald Haeske
About Harald Haeske
Harald Haeske is a Senior Medical Director with extensive experience in clinical development, having held various leadership roles in the pharmaceutical and biotechnology industries across multiple countries.
Current Roles at Bristol Myers Squibb and Nuveea AG
Harald Haeske is currently serving as a Senior Medical Director at Bristol Myers Squibb. In addition to his role there, he is the Founder and Owner of Nuveea AG, where he works as an Independent Consultant in Early Clinical Development. His involvement in these roles highlights his extensive expertise in clinical development and leadership within the pharmaceutical industry.
Previous Experience at Telix Pharmaceuticals Limited and Cantargia AB
Harald Haeske previously held senior roles in notable pharmaceutical companies. In 2022, he worked as the Vice President of Clinical Science at Telix Pharmaceuticals Limited for nine months. From 2021 to 2022, Haeske served as a Senior Medical Director at Cantargia AB in Lund, Schonen, Sweden, further demonstrating his significant experience in managing clinical sciences and development.
Co-founder Roles and Leadership in the United States and Germany
Harald Haeske has co-founded multiple companies, including Susavox Biotechnologies, Inc., where he served as Chief Executive Officer from 2014 to 2016 in Wilmington, Delaware, USA. He was also a co-founder and held positions as Chief Medical Officer and Chief Business Officer at Volvox Therapeutics GmbH in Munich from 2013 to 2017. These roles exhibit his entrepreneurial spirit and leadership capabilities in the biotech sector.
Educational Background in Medicine, Business, and Law
Harald Haeske's academic credentials are diverse and comprehensive. He holds a State Exam in Medicine from Philipps-Universität Marburg, obtained between 1994 and 2000. He pursued further education at FOM Hochschule für Oekonomie & Management, achieving a Master of Business Administration (MBA) from 2015 to 2018 and a Master of Laws (LLM) specializing in Mergers & Acquisitions from 2016 to 2019. These qualifications underscore his multidisciplinary approach to the life sciences and business sectors.
Interests in Emerging Technologies and Innovations
Harald Haeske has demonstrated a keen interest in exploring new business models and technological advancements within the life sciences industry. His areas of interest include blockchain applications, artificial intelligence, and virtual and augmented reality. Haeske's involvement as an angel investor in these fields reflects his commitment to fostering innovation and staying at the forefront of industry developments.